Cat. No.: HY-W668775

Quin-C7

Customer Review

Based on 1 Customer Validation

Quin-C7 is an orally active FPR2/ALX antagonist. Quin-C7 binds to the orthosteric ligand-binding pocket of FPR2/ALX, modulates receptor activation, and inhibits pro-inflammatory ERK signaling mediated by serum amyloid A (SAA). Quin-C7 reduces pro-inflammatory mediators TNF-α levels, increases anti-inflammatory IL-10, decreases inflammatory neutrophils and pro-inflammatory M1 macrophages, downregulates ERK1/2 phosphorylation, and upregulates JNK1/2/3 phosphorylation. Quin-C7 blocks FPR2/mFpr2 signaling, reduces brain lesion volume. Quin-C7 can be used for the research of inflammatory bowel disease and neuromyelitis optica spectrum disorder.

For research use only. We do not sell to patients.

Purity: 99.76%
CAS No.: 871100-12-8
Formula: C₂₅H₂₅N₃O₄
Molecular Weight:431.48

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Quin-C7 Chemical Structure

CAS No.: 871100-12-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

ERK1

ERK2

JNK1

JNK2

JNK3

IL-10

All ERK Isoforms :

All JNK Isoforms :

All TNF Receptor Isoforms :

All Interleukin Related Isoforms :

In Vitro

Quin-C7 binds with high affinity to human FPR2/ALX, forming a network of polar and stacking interactions with receptor residues, including a unique hydrogen bond with Q258^6.52^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Quin-C7 (0.512-320 mg/kg; I.g.; daily; 7 days) ameliorates DSS (HY-116282C)-induced acute colitis in male C57BL/6N mice with an ED₅₀ of 2.2110 mg/kg for symptomatic DAI improvement, via modulation of myeloid cell activity and ERK/JNK signaling pathways^[1].
Quin-C7 (16-32 mg/kg; i.g.; daily; 4 days) significantly reduces pathology in NMOSD mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6N (male, SPF grade, 7-8 weeks old, body weight 21 g, DSS-induced acute colitis)^[1]
Dosage:

0.512 mg/kg; 2.56 mg/kg; 12.8 mg/kg; 64 mg/kg; 320 mg/kg; 16 mg/kg; 160 mg/kg
Administration:

i.g.; daily; 7 days
Result:

Reduced weight loss and decreased Disease Activity Index (DAI) compared to vehicle-treated colitis mice.
Showed an ED₅₀ for symptomatic amelioration (DAI loss) was 2.2110 mg/kg, and ED₅₀ for weight recovery was 1.1430 mg/kg.
Reduced colonic tissue damage, immune cell infiltration, and histopathological scores compared to vehicle-treated colitis mice.
Reversed DSS-induced colon shortening compared to vehicle-treated colitis mice.
Reduced colonic TNF-α levels, increased colonic IL-10 levels, and reduced colonic myeloperoxidase (MPO) and Ly6G levels compared to vehicle-treated colitis mice.
Reduced splenic neutrophil (CD45+ CD11b+ Ly6G+) fractions, reduced colonic neutrophil fractions and median Ly6G fluorescence intensity, and reduced colonic F4/80+ CD86+ (M1 macrophage) cell fractions compared to vehicle-treated colitis mice.
Decreased phosphorylation levels of colonic ERK1/2 and increased phosphorylation levels of colonic JNK1/2/3 compared to vehicle-treated colitis mice.
Showed no significant change in colonic p38 phosphorylation.

Animal Model:

C57BL/6 (8-10 weeks of age; NMOSD induced by intracerebral infusion of AQP4-IgG and human complement)^[2]
Dosage:

16 mg/kg; 32 mg/kg
Administration:

i.g.; daily; 4 days
Result:

Significantly reduced loss of AQP4, GFAP, and MBP, and brain lesion volume at 32 mg/kg/day.
Reduced the absolute number of B cells and NK cells in the spleen, and the absolute number of microglia and infiltrating CD4⁺ T cells in the brain.
Increased the percentage of microglia expressing anti-inflammatory factors IL-10 and TGF-β.
Decreased the percentage of microglia expressing pro-inflammatory factors IL-6 and TNF-α.

Chemical Information

CAS No. 871100-12-8
Appearance Solid
Molecular Weight 431.48
Formula C₂₅H₂₅N₃O₄
Color White to off-white
SMILES

CCCCOC1=CC=C(C(NN2C(C3=CC=C(C=C3)O)NC4=CC=CC=C4C2=O)=O)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (231.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3176 mL

11.5880 mL

23.1760 mL

5 mM

0.4635 mL

2.3176 mL

4.6352 mL

10 mM

0.2318 mL

1.1588 mL

2.3176 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (11.59 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (11.59 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Yang WS, et al. Oral FPR2/ALX modulators tune myeloid cell activity to ameliorate mucosal inflammation in inflammatory bowel disease. Acta Pharmacol Sin. 2025;46(7):1958-1973. [Content Brief]

[2]. Qi C, et al. Targeting formyl peptide receptor 2 to suppress neuroinflammation in neuromyelitis optica spectrum disorder. Theranostics. 2025;15(10):4495-4506. Published 2025 Mar 19. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3176 mL	11.5880 mL	23.1760 mL	57.9401 mL
	5 mM	0.4635 mL	2.3176 mL	4.6352 mL	11.5880 mL
	10 mM	0.2318 mL	1.1588 mL	2.3176 mL	5.7940 mL
	15 mM	0.1545 mL	0.7725 mL	1.5451 mL	3.8627 mL
	20 mM	0.1159 mL	0.5794 mL	1.1588 mL	2.8970 mL
	25 mM	0.0927 mL	0.4635 mL	0.9270 mL	2.3176 mL
	30 mM	0.0773 mL	0.3863 mL	0.7725 mL	1.9313 mL
	40 mM	0.0579 mL	0.2897 mL	0.5794 mL	1.4485 mL
	50 mM	0.0464 mL	0.2318 mL	0.4635 mL	1.1588 mL
	60 mM	0.0386 mL	0.1931 mL	0.3863 mL	0.9657 mL
	80 mM	0.0290 mL	0.1449 mL	0.2897 mL	0.7243 mL
	100 mM	0.0232 mL	0.1159 mL	0.2318 mL	0.5794 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Quin-C7

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Neuronal Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Pancreatic Cancer Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Macrophage Related Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

All ERK Isoforms

All JNK Isoforms

All TNF Receptor Isoforms

All Interleukin Related Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Quin-C7 Related Classifications

HY-W668775 Related Classifications